Table 6 Percentage retail mark-up on antimalarials in drug stores by area
ADDO regions | Non-ADDO regions | |||
|---|---|---|---|---|
N | Median Mark-up [IQR] | N | Median Mark-up [IQR] | |
Artemether lumefantrine | ||||
Subsidiseda tablets | 75 | 60.0 [33.3–78.6] | 90 | 66.7 [42.9–87.5] |
Unsubsidised tablets | 6 | 100.0 [66.7–102.5] | 5 | 53.1 [50.0–66.7]* |
Unsubsidised non-tablets | 3 | 28.20 [20.0–47.1] | 6 | 47.06 [33.3–50.0] |
Other ACTs | ||||
Tablets | 22 | 42.9 [32.2–53.8] | 45 | 33.3 [− 61.1–66.7] |
Non-tablets | 0 | – | 1 | 11.1 |
Artemisinin monotherapies | ||||
Non-tabletsb | 1 | 50.0 | 0 | – |
Non-artemisinin therapies | ||||
Tablets | 141 | 81.8 [28.6–100.0] | 167 | 87.5 [33.3–110.5] |
Non-tablets | 112 | 66.7 [42.9–87.5] | 136 | 50.0 [33.3–81.8] |